SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biomarker

PUBLISHER: Grand View Research | PRODUCT CODE: 2132499

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2132499

Blood-based Biomarkers Market Size, Share & Trends Analysis Report By Type (Genetic Biomarkers, Protein Biomarkers), By Application (Cancer, Cardiovascular Diseases), By Technology, By End-use, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Blood-based Biomarkers Market Summary

The global blood-based biomarkers market size was valued at USD 8.7 billion in 2025 and is projected to grow from USD 9.3 billion in 2026 to USD 15.3 billion by 2033, at a CAGR of 7.4% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 42.6% in 2025. The market is driven by the growing adoption of precision medicine, increasing use of minimally invasive diagnostics, and advancements in molecular diagnostic technologies such as NGS and digital PCR.

Furthermore, the rising burden of cancer and neurological disorders, along with the integration of multi-omics platforms and AI-based biomarker analysis, is supporting broader clinical adoption of blood-based biomarkers.

Global Blood-based Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood-based biomarkers market report based on type, application, technology, end use, and region.

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Genetic Biomarkers
  • Protein Biomarkers
  • Metabolic Biomarkers
  • Cell-Based Biomarkers
  • Epigenetic Biomarkers
  • Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cancer
  • Cardiovascular Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Others
  • Technology Outlook (Revenue, USD Billion, 2021 - 2033)
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Immunoassays
  • Mass Spectrometry
  • Others
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
  • Others
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68040-519-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. Technology
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type, application, technology, and end use outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood Based Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of chronic diseases
      • 3.2.1.2. Advancements in biomarker technology
      • 3.2.1.3. Expanding research and funding support
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High development and validation costs
      • 3.2.2.2. Lack of reimbursement policies for biomarker treatment
  • 3.3. Blood Based Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Social landscape
      • 3.3.2.5. Environmental landscape

Chapter 4. Blood Based Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Global Blood Based Biomarkers Market: Type Dashboard
  • 4.2. Global Blood Based Biomarkers Market: Type Movement Analysis
  • 4.3. Global Blood Based Biomarkers Market by Type, Revenue
  • 4.4. Genetic Biomarkers
    • 4.4.1. Genetic Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.5. Protein Biomarkers
    • 4.5.1. Protein Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.6. Metabolic Biomarkers
    • 4.6.1. Metabolic Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.7. Cell-Based Biomarkers
    • 4.7.1. Cell-Based Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.8. Epigenetic Biomarkers
    • 4.8.1. Epigenetic Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Blood Based Biomarkers Market: Application Estimates & Trend Analysis

  • 5.1. Global Blood Based Biomarkers Market: Application Dashboard
  • 5.2. Global Blood Based Biomarkers Market: Application Movement Analysis
  • 5.3. Global Blood Based Biomarkers Market by Application , Revenue
  • 5.4. Cancer
    • 5.4.1. Cancer market estimates and forecasts 2021 to 2033 (USD Billion)
  • 5.5. Cardiovascular Diseases
    • 5.5.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Billion)
  • 5.6. Neurological Diseases
    • 5.6.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Billion)
  • 5.7. Immunological Diseases
    • 5.7.1. Immunological diseases market estimates and forecasts 2021 to 2033 (USD Billion)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 6. Blood Based Biomarkers Market: Technology Estimates & Trend Analysis

  • 6.1. Global Blood Based Biomarkers Market: Technology Dashboard
  • 6.2. Global Blood Based Biomarkers Market: Technology Movement Analysis
  • 6.3. Global Blood Based Biomarkers Market by Technology , Revenue
  • 6.4. Next-Generation Sequencing
    • 6.4.1. Next-Generation Sequencing market estimates and forecasts 2021 to 2033 (USD Billion)
  • 6.5. Polymerase Chain Reaction
    • 6.5.1. Polymerase Chain Reaction market estimates and forecasts 2021 to 2033 (USD Billion)
  • 6.6. Immunoassays
    • 6.6.1. Immunoassays market estimates and forecasts 2021 to 2033 (USD Billion)
  • 6.7. Mass Spectrometry
    • 6.7.1. Mass Spectrometry market estimates and forecasts 2021 to 2033 (USD Billion)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 7. Blood Based Biomarkers Market: End Use Estimates & Trend Analysis

  • 7.1. Global Blood Based Biomarkers Market: End Use Dashboard
  • 7.2. Global Blood Based Biomarkers Market: End Use Movement Analysis
  • 7.3. Global Blood Based Biomarkers Market by End Use, Revenue
  • 7.4. Hospitals & Clinics
    • 7.4.1. Hospitals & clinics market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5. Diagnostic Laboratories
    • 7.5.1. Diagnostic laboratories market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.6. Research & Academic Institutes
    • 7.6.1. Research & academic institutes market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.7. Others
    • 7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 8. Blood Based Biomarkers Market: Regional Estimates & Trend Analysis by Type, Application, Technology, and End Use

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Billion)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Abbott
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. BIOMERIEUX
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. F. Hoffmann-La Roche Ltd.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Siemens Healthineers AG
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Thermo Fisher Scientific, Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Bio-Rad Laboratories, Inc
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Cleveland Diagnostics, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Sysmex Corporation
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-519-1

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Abbreviations
  • Table 3 Global Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 4 Global Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 5 Global Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 6 Global Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 7 Global Blood Based Biomarkers, by Region, 2021 - 2033 (USD Billion)
  • Table 8 North America Blood Based Biomarkers, by Country, 2021 - 2033 (USD Billion)
  • Table 9 North America Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 10 North America Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 11 North America Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 12 North America Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 13 U.S. Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 14 U.S. Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 15 U.S. Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 16 U.S. Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 17 Canada Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 18 Canada Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 19 Canada Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 20 Canada Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 21 Mexico Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 22 Mexico Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 23 Mexico Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 24 Mexico Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 25 Europe Blood Based Biomarkers, by Country, 2021 - 2033 (USD Billion)
  • Table 26 Europe Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 27 Europe Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 28 Europe Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 29 Europe Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 30 Germany Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 31 Germany Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 32 Germany Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 33 Germany Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 34 UK Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 35 UK Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 36 UK Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 37 UK Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 38 France Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 39 France Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 40 France Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 41 France Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 42 Italy Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 43 Italy Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 44 Italy Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 45 Italy Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 46 Spain Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 47 Spain Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 48 Spain Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 49 Spain Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 50 Denmark Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 51 Denmark Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 52 Denmark Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 53 Denmark Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 54 Sweden Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 55 Sweden Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 56 Sweden Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 57 Sweden Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 58 Norway Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 59 Norway Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 60 Norway Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 61 Norway Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 62 Asia Pacific Blood Based Biomarkers, by Country, 2021 - 2033 (USD Billion)
  • Table 63 Asia Pacific Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 64 Asia Pacific Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 65 Asia Pacific Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 66 Asia Pacific Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 67 China Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 68 China Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 69 China Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 70 China Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 71 Japan Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 72 Japan Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 73 Japan Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 74 Japan Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 75 India Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 76 India Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 77 India Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 78 India Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 79 South Korea Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 80 South Korea Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 81 South Korea Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 82 South Korea Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 83 Australia Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 84 Australia Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 85 Australia Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 86 Australia Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 87 Thailand Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 88 Thailand Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 89 Thailand Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 90 Thailand Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 91 Latin America Blood Based Biomarkers, by Country, 2021 - 2033 (USD Billion)
  • Table 92 Latin America Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 93 Latin America Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 94 Latin America Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 95 Latin America Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 96 Brazil Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 97 Brazil Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 98 Brazil Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 99 Brazil Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 100 Argentina Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 101 Argentina Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 102 Argentina Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 103 Argentina Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 104 Middle East & Africa Blood Based Biomarkers, by Country, 2021 - 2033 (USD Billion)
  • Table 105 Middle East & Africa Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 106 Middle East & Africa Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 107 Middle East & Africa Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 108 Middle East & Africa Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 109 South Africa Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 110 South Africa Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 111 South Africa Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 112 South Africa Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 113 Saudi Arabia Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 114 Saudi Arabia Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 115 Saudi Arabia Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 116 Saudi Arabia Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 117 UAE Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 118 UAE Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 119 UAE Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 120 UAE Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)
  • Table 121 Kuwait Blood Based Biomarkers, by Type, 2021 - 2033 (USD Billion)
  • Table 122 Kuwait Blood Based Biomarkers, by Application, 2021 - 2033 (USD Billion)
  • Table 123 Kuwait Blood Based Biomarkers, by Technology, 2021 - 2033 (USD Billion)
  • Table 124 Kuwait Blood Based Biomarkers, by End Use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Blood Based Biomarkers Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Global Blood Based Biomarkers Market: Type Movement Analysis
  • Fig. 16 Global Blood Based Biomarkers Market, for Genetic Biomarkers, 2021 - 2033 (USD Billion)
  • Fig. 17 Global Blood Based Biomarkers Market, for Protein Biomarkers, 2021 - 2033 (USD Billion)
  • Fig. 18 Global Blood Based Biomarkers Market, for Metabolic Biomarkers, 2021 - 2033 (USD Billion)
  • Fig. 19 Global Blood Based Biomarkers Market, for Cell-Based Biomarkers, 2021 - 2033 (USD Billion)
  • Fig. 20 Global Blood Based Biomarkers Market, for Epigenetic Biomarkers, 2021 - 2033 (USD Billion)
  • Fig. 21 Global Blood Based Biomarkers Market, for Application, 2021 - 2033 (USD Billion)
  • Fig. 22 Global Blood Based Biomarkers Market, for Cancer, 2021 - 2033 (USD Billion)
  • Fig. 23 Global Blood Based Biomarkers Market, for Cardiovascular Diseases, 2021 - 2033 (USD Billion)
  • Fig. 24 Global Blood Based Biomarkers Market, for Neurological Diseases, 2021 - 2033 (USD Billion)
  • Fig. 25 Global Blood Based Biomarkers Market, for Immunological Diseases, 2021 - 2033 (USD Billion)
  • Fig. 26 Global Blood Based Biomarkers Market, for Others, 2021 - 2033 (USD Billion)
  • Fig. 27 Global Blood Based Biomarkers Market, for Technology, 2021 - 2033 (USD Billion)
  • Fig. 28 Global Blood Based Biomarkers Market, for Next-Generation Sequencing, 2021 - 2033 (USD Billion)
  • Fig. 29 Global Blood Based Biomarkers Market, for Polymerase Chain Reaction, 2021 - 2033 (USD Billion)
  • Fig. 30 Global Blood Based Biomarkers Market, for Immunoassays, 2021 - 2033 (USD Billion)
  • Fig. 31 Global Blood Based Biomarkers Market, for Mass Spectrometry, 2021 - 2033 (USD Billion)
  • Fig. 32 Global Blood Based Biomarkers Market, for Others, 2021 - 2033 (USD Billion)
  • Fig. 33 Global Blood Based Biomarkers Market: End Use Movement Analysis
  • Fig. 34 Global Blood Based Biomarkers Market, for Hospitals & Clinics, 2021 - 2033 (USD Billion)
  • Fig. 35 Global Blood Based Biomarkers Market, for Diagnostic Laboratories, 2021 - 2033 (USD Billion)
  • Fig. 36 Global Blood Based Biomarkers Market, for Research & Academic Institutes, 2021 - 2033 (USD Billion)
  • Fig. 37 Global Blood Based Biomarkers Market, for Others, 2021 - 2033 (USD Billion)
  • Fig. 38 Regional Marketplace: Key Takeaways
  • Fig. 39 Regional Outlook, 2024 & 2033
  • Fig. 40 Global Blood Based Biomarkers Market: Region Movement Analysis
  • Fig. 41 North America Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 42 U.S. Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 43 Canada Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 44 Mexico Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 45 Europe Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 46 Germany Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 47 UK Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 48 France Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 49 Italy Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 50 Spain Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 51 Denmark Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 52 Sweden Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 53 Norway Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 54 Asia Pacific Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 55 Japan Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 56 China Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 57 India Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 58 Australia Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 59 South Korea Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 60 Thailand Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 61 Latin America Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 62 Brazil Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 63 Argentina Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 64 Middle East and Africa Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 65 South Africa Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 66 Saudi Arabia Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 67 UAE Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
  • Fig. 68 Kuwait Blood Based Biomarkers Market, 2021 - 2033 (USD Billion)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!